Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00195377
NCT00195377CompletedNot Applicable

Evaluating Safety and QoL in Patients Treated With Etanercept: an Open Multicenter Study

Wyeth is now a wholly owned subsidiary of Pfizer0 sites1,000 target enrollmentStarted: April 2003Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
1,000
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to assess the safety of etanercept in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA) in Spain

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
4 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •RA or PsA in whom DMARDs/antiTNF antibodies/anti IL1 has been insufficient or inappropriate
  • •Children from 4 to 17 years old with JIA polyarticular

Exclusion Criteria

  • •Clinically significant abnormal screening lab values
  • •Patients who are planning to undergo elective surgery during the study period.
  • •Other current autoimmune connective tissue diseases

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor Class
Industry

Similar Trials

Completed
Not Applicable
Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in SpainInflammationRheumatoid Arthritis
NCT00195364Wyeth is now a wholly owned subsidiary of Pfizer93
Completed
Not Applicable
Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics RegistryRheumatoid Arthritis
NCT01646385Pfizer6,393
Completed
Phase 4
Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic TreatmentsPsoriasis
NCT00967538Innovaderm Research Inc.89
Unknown
Not Applicable
Safety and Efficacy of Etanercept in Patients With PsoriasisPsoriasis
NCT02258282Chengdu PLA General Hospital80
Completed
Phase 4
CAMEO: Canadian Methotrexate and Etanercept Outcome StudyRheumatoid Arthritis
NCT00654368Amgen258
Study Evaluating Etanercept in Patients... | Clinical Trial